The Role of Programmed Cell Death Receptor 1 in Lung Cancer

被引：3

作者：

Badiu, Dumitru Cristinel ^{[1
]}

Zgura, Anca ^{[2
]}

Mehedintu, Claudia ^{[3
]}

Haineala, Bogdan ^{[4
]}

Anghel, Rodica ^{[2
]}

Bacinschi, Xenia ^{[2
]}

机构：

[1] Carol Davila Univ Med & Pharm, Dept Gen Surg, Bagdasar Arseni Clin Emergency Hosp, Bucharest, Romania

[2] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Obstet Radiotherapy, Bucharest, Romania

[3] Carol Davila Univ Med & Pharm, Dept Obstet & Gynecol, Malaxa Clin Hosp, Bucharest, Romania

[4] Carol Davila Univ Med & Pharm, Dept Urol, Fundeni Clin Inst, Bucharest, Romania

来源：

IN VIVO | 2022年 / 36卷 / 02期

关键词：

Lung cancer; immune cells; lymphocytes; chemotherapy; programmed death 1; PD-L1; EXPRESSION; PROGNOSTIC-SIGNIFICANCE; ASSOCIATION;

D O I：

10.21873/invivo.12794

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed death ligand 1 (PD-L1) expression were observed on non-small-cell lung cancer. The association between PD-L1 expression and clinicopathological characteristics in lung cancer is still unclear. Patients and Methods: This is a cross-sectional, observational study that evaluated a sample of 41 lung cancer patients diagnosed between March 2019 and December 2020. PD-L1 tumor expression is described as a percentage. Results: Patients were diagnosed with nonmicrocellular lung cancer and aged 37 to 87 years. Most patients were diagnosed with adenocarcinoma. According to the analysis, the average age of patients with negative PDL1 tumors was 65.6 years, and of those with positive PD-L1 tumors was 63.6 years. The average value of the tumor proportion score for males was 26.97%, and for females 25.55%. Conclusion: No correlation was found between PDL1 tumor expression and the age and sex of patients.

引用

页码：1007 / 1012

页数：6

共 20 条

[11] Metastatic sites and survival in lung cancer [J].

Riihimaeki, M. ;

Hemminki, A. ;

Fallah, M. ;

Thomsen, H. ;

Sundquist, K. ;

Sundquist, J. ;

Hemminki, K. .

LUNG CANCER, 2014, 86 (01) :78-84

[12] Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol [J].

Robbins, Hilary A. ;

Callister, Matthew ;

Sasieni, Peter ;

Quaife, Samantha L. ;

Cheung, Li C. ;

Brennan, Paul ;

Katki, Hormuzd A. ;

Berg, Christine D. ;

Baldwin, David ;

Johansson, Mattias .

LANCET RESPIRATORY MEDICINE, 2019, 7 (08) :655-656

[13] SAFE SURGERY IN DAY CARE CENTERS: FOCUS ON PREVENTING MEDICAL LEGAL ISSUES [J].

Serban, Dragos ;

Branescu, Cristian Mihai ;

Smarandache, Gabriel Catalin ;

Tudor, Corneliu ;

Tanasescu, Ciprian ;

Tudosie, Mihai Silviu ;

Stana, Daniela ;

Costea, Daniel Ovidiu ;

Dascalu, Ana Maria ;

Spataru, Radu Iulian .

ROMANIAN JOURNAL OF LEGAL MEDICINE, 2021, 29 (01) :60-64

[14] Screening for lung cancer: time for large-scale screening by chest computed tomography [J].

Shlomi, Dekel ;

Ben-Avi, Ronny ;

Balmor, Gingy Ronen ;

Onn, Amir ;

Peled, Nir .

EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (01) :217-238

[15] Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].

Sung, Hyuna ;

Ferlay, Jacques ;

Siegel, Rebecca L. ;

Laversanne, Mathieu ;

Soerjomataram, Isabelle ;

Jemal, Ahmedin ;

Bray, Freddie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249

[16] The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs [J].

Tang, Yanna ;

Fang, Wenfeng ;

Zhang, Yaxiong ;

Hong, Shaodong ;

Kang, Shiyang ;

Yan, Yue ;

Chen, Nan ;

Zhan, Jianhua ;

He, Xiaobo ;

Qin, Tao ;

Li, Ge ;

Tang, Wenyi ;

Peng, Peijian ;

Zhang, Li .

ONCOTARGET, 2015, 6 (16) :14209-14219

[17] PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis [J].

Tuminello, Stephanie ;

Sikavi, Daniel ;

Veluswamy, Rajwanth ;

Gamarra, Cesar ;

Lieberman-Cribbin, Wil ;

Flores, Raja ;

Taioli, Emanuela .

TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) :1343-+

[18] Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy [J].

Vrankar, Martina ;

Kern, Izidor ;

Stanic, Karmen .

RADIATION ONCOLOGY, 2020, 15 (01)

[19] The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis [J].

Wang, A. ;

Wang, H. Y. ;

Liu, Y. ;

Zhao, M. C. ;

Zhang, H. J. ;

Lu, Z. Y. ;

Fang, Y. C. ;

Chen, X. F. ;

Liu, G. T. .

EJSO, 2015, 41 (04) :450-456

[20] PD-L1 Expression in Lung Cancer [J].

Yu, Hui ;

Boyle, Theresa A. ;

Zhou, Caicun ;

Rimm, David L. ;

Hirsch, Fred R. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) :964-975

← 1 2 →